ArticleEMBO reports2019
HRAS-driven cancer cells are vulnerable to TRPML1 inhibition.
Open access · bronzeAbstract read
In one paragraph
Article in EMBO reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 84 citations in OpenAlex.
- How to Perform a Tracer Displacement BRET Assay for the TRPML1 Ion Channel.Bio-protocol · 2026Article
- Regulation of Ferroptosis Sensitivity in Hepatocellular Carcinoma Cells by Lysosomal Ion Channels TPC2 and TRPML1.Antioxidants (Basel, Switzerland) · 2026Article
- Physiological functions and pharmacological targeting of transient receptor potential channels.Pharmacological reviews · 2025Review
- TRPML1 ion channel promotes HepaRG cell differentiation under simulated microgravity conditions.NPJ microgravity · 2025Article
- TPC2: From Blond Hair to Melanoma?Cancers · 2024Review
- CaBiophysics reports · 2024Article
- Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization.Cell death & disease · 2024Article
- Inhibition of lysosomal TRPML1 channel eliminates breast cancer stem cells by triggering ferroptosis.Cell death discovery · 2024Article
- Metabolomic Approach to Identify Potential Biomarkers in KRAS-Mutant Pancreatic Cancer Cells.Biomedicines · 2024Article
- Impact of Obesity and Lysosomal Dysfunction on Chemoresistance in Ovarian Cancer.Biomedicines · 2024Review
- Review
- Conformational States of the GDP- and GTP-Bound HRAS Affected by A59E and K117R: An Exploration from Gaussian Accelerated Molecular Dynamics.Molecules (Basel, Switzerland) · 2024Article
- Article
- Pan-cancer ion transport signature reveals functional regulators of glioblastoma aggression.The EMBO journal · 2024Article
- TRP Channels in Cancer: Signaling Mechanisms and Translational Approaches.Biomolecules · 2023Review
- RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment.Journal of translational medicine · 2023Review
- Epitranscriptic regulation ofProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer.Journal of translational medicine · 2023Article
- Lysosomal Potassium Channels.Handbook of experimental pharmacology · 2023Review
- TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review.Frontiers in oncology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 4 institutions in 1 country.
Jewon JungDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Kwang-Jin ChoDepartment of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.
Ali K NajiDepartment of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center, Houston, TX, USA.
Kristen N ClemonsDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Ching On WongDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Mariana VillanuevaBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA.
Steven GregoryDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Nicholas E KaragasDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Lingxiao TanDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Hong LiangDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Morgan A RousseauDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Kelly M TomasevichDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Andrew G SikoraBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA.
Ilya LeventalDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Dharini van der HoevenDepartment of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center, Houston, TX, USA.
Yong ZhouDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
John F HancockDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
Kartik VenkatachalamDepartment of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA Kartik.venkatachalam@uth.tmc.edu.ORCID 0000-0002-3055-9265
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · USBaylor College of Medicine · USWright State University · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MAlterations in synaptic growth and lipid-raft organization in a fly MLIV modelR01NS081301 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI VENKATACHALAM, KARTIK · 2014 to 2018
$1.7MK-Ras plasma membrane interactions: a tractable therapeutic targetR00CA188593 · NCI · WRIGHT STATE UNIVERSITY · PI CHO, KWANGJIN · 2017 to 2019
$747kGDAP1 mediated cellular damage in MLIVR21NS094860 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KISELYOV, KIRILL, VENKATACHALAM, KARTIK · 2016 to 2017
$428kNCI NIH HHS P30 CA125123NCI NIH HHS R00 CA188593NINDS NIH HHS R01 NS081301NINDS NIH HHS R21 NS094860
Abstract
By serving as intermediaries between cellular metabolism and the bioenergetic demands of proliferation, endolysosomes allow cancer cells to thrive under normally detrimental conditions. Here, we show that an endolysosomal TRP channel, TRPML1, is necessary for the proliferation of cancer cells that bear activating mutations in
Indexed as
AnimalsCalciumCalcium SignalingCell MembraneCell ProliferationDrosophilaEndosomesExtracellular Signal-Regulated MAP KinasesGene ExpressionGene Regulatory NetworksHumansLysosomesModels, BiologicalMutationNeoplasmsPhosphorylationCalciumExtracellular Signal-Regulated MAP KinasesHRAS protein, humanMCOLN1 protein, humanProto-Oncogene Proteins p21(ras)Transient Receptor Potential ChannelscancercholesterolendolysosomesHRASTRPML1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.